Sceletium tortuosum
Dual-mechanism mood & cognitive botanical — clinically studied, regulatory-cleared in North America.
Sceletium tortuosum (Mesembryanthemum tortuosum L.) — commonly known as kanna, kougoed, or channa — is a low-growing succulent herb endemic to the dry Karoo and Namaqualand regions of South Africa's Western and Northern Cape. It has been part of San and Khoikhoi material culture for at least four centuries of recorded history. Commercial cultivation from cutting propagation has been established since 2000, alongside continued wild-collection supply.
Primary Constituents
Mesembrine, mesembrenone, mesembrenol, mesembranol, delta-7-mesembrenone
Market Context
Kanna product launches grew roughly 300% in 2024 across the supplement, beverage, and functional-food categories. Asia-Pacific is projected to be the fastest-growing regional market through 2034, with China, Japan, and South Korea as primary targets once a regulatory pathway opens. Its dual mechanism — serotonin reuptake inhibition plus PDE4 inhibition — combined with fMRI evidence that a single dose measurably calms the brain's threat response, gives it a differentiated "calm and social ease" positioning that single-action botanicals like ashwagandha cannot claim.
Four categories describe the plant and its upstream supply chain and don't change by format. Four change depending on whether Sceletium ships as a supplement, a beverage, or a solid food.
Full rating definitions are in the "How Ratings Are Defined" methodology, included in the downloadable report.
Kanna's psychoactivity comes from a family of mesembrine-type alkaloids, not a single compound. Commercial standardization controls for both total alkaloid content (0.35–0.45% for standardized extract) and the relative proportion of individual alkaloids to one another, because the two underlying mechanisms — serotonin reuptake inhibition and PDE4 inhibition — are not carried equally by each alkaloid.
| Compound Name | Primary Activity | Potency Data | Physiological Association |
|---|---|---|---|
| Mesembrine | Dominant SERT inhibitor | Ki = 1.4 nM, most potent tested | Drives mood/anxiolytic effects |
| Mesembrenone | Dominant PDE4B inhibitor | IC50 0.47 µg/mL, ~17x more potent than mesembrine at this target | Drives cognitive/executive-function effects |
| Mesembrenol | Weak PDE4B inhibitor | IC50 16 µg/mL, weakest of the three quantified | Minor contributor |
| Mesembranol | Contributing alkaloid | Validated analytically, potency not separately quantified | Assumed to add to overall activity; contribution unclear |
| Delta-7-mesembrenone | Contributing alkaloid | Validated analytically, potency not separately quantified | Assumed to add to overall activity; contribution unclear |
| Tortuosamine | Structurally distinct minor alkaloid | No potency data identified | Contribution not established |
Full sourcing and the complete caveat discussion are included in the downloadable report.
Every formal clinical study to date has been conducted in healthy volunteers rather than clinical populations, and all dosing was via capsule. This category rates Green regardless of end use.
| Benefit | Key Finding | Evidence Level | Rating |
|---|---|---|---|
| Anxiety reduction | 6-week RCT, n=60, HAM-A significantly lower at 50 mg/day (p=0.03) | RCT — Strong | |
| Cognitive function | 3-week crossover RCT, n=21, executive function (p<0.022) and set flexibility (p<0.032) improved | RCT — Strong | |
| Stress resilience | fMRI, n=16, amygdala reactivity attenuated (p<0.01) | RCT — Strong | |
| Mood elevation | Positive mood reported as secondary outcome across trials | Traditional + clinical | |
| Sleep quality | Improved sleep noted as secondary endpoint | RCT secondary endpoint | |
| Anti-inflammatory | In vitro: increased mitochondrial viability, upregulated IL-10 | In vitro — Preliminary | |
| Safety profile | 3-month study, n=37, no significant adverse events, no withdrawal on cessation | RCT — Strong |
Regulatory treatment varies sharply by jurisdiction and, within a jurisdiction, by end use — see the Scorecard's Regulatory Approval card above for the full country × end-use grid. Summary by market:
| End Use | Status | Notes |
|---|---|---|
| United States | ||
| Dietary Supplement | Cleared | Self-affirmed GRAS (2011) + NDI on file; 40+ listed products. |
| Canada | ||
| Dietary Supplement | Cleared | 11 active NHP licences with a cognitive-function claim. |
| South Africa | ||
| All end uses | Conditional | ABS/bioprospecting permit + benefit-sharing agreement required for every transaction. |
| European Union | ||
| Dietary Supplement | Conditional | Pending novel-food dossier scoped to supplements only, 25 mg/day. |
| Beverage | Restricted | Pending novel-food dossier scoped to supplements only, 25 mg/day. |
| Australia | ||
| All end uses | Restricted | Not on TGA's pre-assessed permissible-ingredients list. |
| Russia | ||
| All end uses | Restricted | Mesembrine scheduled as a psychotropic substance — the most conservative precedent in the dataset. |
| China | ||
| All end uses | Restricted | No NHC application filed; mature B2B export supply chain exists regardless. |
Full country-by-country narrative and sourcing included in the downloadable report.
Quality Gates
Two sequential gates stand between raw supply and a national beverage launch: a South African ABS/benefit-sharing permit (5–10 years), and food authorization abroad (3–5 years). Both depend on the same underlying asset — a clinically substantiated, standardized extract currently concentrated in one branded extract (Zembrin).
Download Full Report
Everything on this page, plus complete country-by-country regulatory analysis, full alkaloid sourcing, and the full ratings methodology — as a single downloadable PDF.
What’s included:
- 13-page comprehensive report with table of contents
- Full regulatory narrative for all 7 markets assessed
- Complete sourcing for every clinical and market claim
Free — no account required